TinyGemsBreaks Archive - Page 21 of 123

WednesdayMay 29, 2024 1:44 pm

TinyGemsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) CEO to Participate at Upcoming BIO International Convention 2024

Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, will be spotlighted at next month’s BIO International Convention 2024. The conference is scheduled for June 3–6, 2024, in San Diego. According to the announcement, Predictive Oncology CEO Raymond Vennare will be presenting a company overview at the gathering. His presentation, titled “Novel AI Driven Insights to Guide Early Drug Discovery,” is slated to begin at 6:45 EDT on June 3, 2023. “We are very pleased to participate in this year’s Bio International Convention, which is the premier gathering of biopharmaceutical stakeholders from around the world,” said…

TuesdayMay 28, 2024 3:18 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Developing Zero-Emissions Version of Its PowerUP Mobile EV-Charging Truck

Mullen Automotive (NASDAQ: MULN), an electric vehicle (“EV”) manufacturer, is developing a zero-emissions version of its mobile EV-charging solution, PowerUP. The solution will be available on Mullen’s Class 3 all-electric cab chassis truck. According to the announcement, PowerUp provides increased versatility and 100% zero emissions power generation that can deliver on-demand, mobile DC fast-charging. The company noted that the shift to a 100% zero-emission model represents its commitment to sustainable transportation solutions while also meeting overwhelming market demand for zero-emission options in the mobile EV-charging space. First introduced in 2023 as a mobile EV-charging truck, the original model utilized a…

ThursdayMay 23, 2024 12:06 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is partnering with a contract research organization (“CRO”) to conduct its human pilot study #3. According to the announcement, this is the first-ever DehydraTECH(TM)-processed tirzepatide from Zepbound(R) to be tested in a swallowed oral format. The study is designed to evaluate a dual-action GLP-1 (glucagon-like peptide) plus GIP (glucose-dependent insulintropic peptide) in a randomized, crossover investigation that will compare injected Zepbound tirzepatide by Eli Lilly to a compound formulated, DehydraTECH-processed tirzepatide that is derived from Zepbound but in a capsule form. Test articles for the study will be manufactured…

WednesdayMay 22, 2024 12:02 pm

TinyGemsBreaks – SenesTech Inc. (NASDAQ: SNES) Takes ‘Significant Step’ in Distribution of Flagship Product with Opening of Online Store on Amazon

SenesTech (NASDAQ: SNES), the leader in fertility control to manage animal-pest populations, has launched a dedicated online store on Amazon for Evolve(TM), its minimum-risk, soft bait for the proactive control of rats. Calling the move a “significant step forward in the distribution of Evolve,” the company noted that Evolve addresses the fundamental issue of rodent overpopulation by focusing on their rapid reproduction rates. Numerous independent studies indicate that the active ingredient in Evolve effectively reduces fertility in rodents. Research shows that two rats with sufficient food, water and shelter can produce up to 15,000 offspring within the year, and Evolve…

WednesdayMay 22, 2024 10:56 am

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN), Bollinger Partner with EnviroCharge to Create Innovative Mobile Charging Solution

Mullen Automotive (NASDAQ: MULN), an electric vehicle (“EV”) manufacturer, and Bollinger Motors, a majority-owned company of Mullen, is partnering with EnviroCharge, a provider of convenient and flexible charging solutions, to create an innovative mobile charging solution for electric vehicle fleet owners; the solution enables EV owners to charge their vehicles quickly and easily anytime, anywhere. According to the announcement, Mullen and Bollinger have sold 50 vehicles to EnviroCharge, which will install its mobile, clean-propane-powered charging system on the Bollinger B4 chassis cab, an all-electric Class 4 commercial truck. The agreement between the companies has an estimated deal value of $8,250,000 for…

MondayMay 20, 2024 3:00 pm

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Poised as Go-to Brand for Reliable Cross-Border Shipping in USMCA Region

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a tech company that is transforming cross-border shipping by offering carriers and shippers unmatched flexibility, visibility and simplicity, has been at the forefront of pushing for reliable and dependable ways to organize, facilitate and monitor cross-border shipments, mainly through its Fr8App system. “The Fr8App is supported by artificial intelligence (‘AI’), machine learning and cloud computing, providing an unrivaled freight-matching platform with a real-time portal for B2B cross-border and domestic shipping. With Fr8App, connecting shippers with carriers and drivers is efficient and seamless,” a recent article reads. “Fr8App understands the complexities of cross-border logistics and knows…

MondayMay 20, 2024 1:21 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at 2024 Healthcare Company Showcase

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its Chief Executive Officer John Climaco will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Global Partners. Climaco’s presentation is slated to begin at 1:40 p.m. ET on May 21, 2024. A live webcast will be available on the Events page of CNSP’s website. To view the full press release, visit https://ibn.fm/OSiDy About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company…

MondayMay 20, 2024 11:52 am

TinyGemsBreaks – NextPlat Corp’s (NASDAQ: NXPL) GTC Begins Sales of SpaceX’s Starlink as Authorized Reseller

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced that its subsidiary, Global Telesat Communications Ltd (“GTC”), through a new joint venture agreement with Pivotel Solutions Inc. (dba “Pulsar”) is now a global authorized reseller of SpaceX’s Starlink satellite-based connectivity products. Under the agreement as as an approved reseller, GTC will immediately begin offering Starlink connectivity services in the U.K. and other international markets serving mobile and maritime-based customers. Pulsar will provide GTC back-end systems support services on behalf of its new Starlink customers. “We are pleased to collaborate with Pulsar to begin offering SpaceX’s revolutionary Starlink, LEO-satellite based…

FridayMay 17, 2024 2:46 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Commencement of Dosing in Comprehensive GLP-1 Animal Study

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, reported that dosing has begun in its 12-week animal study, WEIGHT-A24-1. The study is designed to model diabetes treatment and weight-loss effects of DehydraTECH(TM)-processed glucagon-like peptide 1 drugs and DehydraTECH-processed cannabidiol (“CBD”), both alone and in combination in diabetic preconditioned rats. According to the announcement, several new areas of investigation are being explored in this study, including evaluating whether DehydraTECH-processed oral GLP-1 drugs are more effective than non-DehydraTECH-processed oral GLP-1 drugs in reaching brain tissue, improving weight loss and improving control of blood sugar. The study will also evaluate…

ThursdayMay 16, 2024 3:22 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Looking to Tap into Various Growing Markets

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, has proven in numerous studies the ability of its patented DehydraTECH(TM) technology to increase bio-absorption compared to standard industry formulations, as well as reduce time of onset and deliver drugs more effectively across the blood-brain barrier. “DehydraTECH has a number of potential pharmaceutical applications, a testament to its versatility and overall effectiveness. The key factor that has played a role in its adoption is its unique ability to improve drug bioavailability, a critical marker and determinant of overall drug effectiveness,” a recent article reads. “With this technology, Lexaria…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks